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Introduction
The identification of new cancer-promoting genes has yielded 
mechanistic insights into tumor progression and led to the devel-
opment of several targeted therapies. In cutaneous melanoma, the 
finding of common BRAF mutations highlighted the importance 
of ERK pathway activation in tumor initiation and maintenance. 
These studies also triggered the design of vemurafenib and other 
MAPK pathway inhibitors, which were the first drugs to extend the 
survival of patients with advanced disease (1–4). Immunothera-
pies, such as the CTLA4 inhibitor ipilimumab and the PD1 inhib-
itors nivolumab and pembrolizumab (5, 6), have also had a major 
impact on melanoma therapy, as they have dramatically improved 
the long-term survival rates of patients with advanced-stage dis-
ease (7, 8). Despite this progress, many patients do not respond to 
certain therapies, whereas others suffer from drug toxicity, thera-
py resistance, or disease relapse (9–11), underscoring the need to 
identify additional targets for therapeutic intervention.
Along with identifying BRAF and other recurrently mutated 
cancer genes, sequencing strategies have also defined genom-
ic intervals subject to recurrent copy number variations (CNVs). 
However, cancer-promoting genes in CNVs have been difficult 
to identify, because (a) they are often not affected by point muta-
tions, and (b) they are typically present in large CNVs alongside 
several bystander genes that have no effect on tumor progression. 
Analysis of CNVs has the potential to uncover several new can-
cer-promoting genes in solid tumors such as melanomas, in which 
a large percentage of the genome is subject to recurrent CNV (12).
Oncogenomic studies have also revealed expression profiles 
that reflect broad changes in cellular identity that distinguish can-
cer cells from normal tissue (13). In many cancers, tumor cells adopt 
cellular and molecular identities that overlap with their lineally 
related embryonic cells. Adopting these identities can endow tumor 
cells with properties, such as the ability to proliferate or migrate, not 
found in their differentiated counterparts (14–16). Reawakening of 
neural crest character in nascent melanomas, as exemplified by the 
expression of the neural crest specification factors SNAI2 (SLUG) and 
BRN3A (POU4F1) has been shown to enable protumorigenic prop-
erties like migration and survival, respectively (17, 18). Subsequent 
studies have noted additional gene expression and functional rela-
tionships between melanoma and neural crest cells (19, 20). Whereas 
similarities between tumor and embryonic cells in melanomas and 
other cancers have been recognized, the factors that establish and 
maintain an embryonic identity in tumor cells are poorly understood. 
Specifically, it is not clear whether embryonic genes are regulated sep-
arately to reconstitute an embryonic identity or whether a program-
matic change that simultaneously regulates many genes is involved. 
In addition, the consequences of abrogating embryonic identity in 
melanoma and other cancers have not been thoroughly investigated.
In this study, we report the identification of the growth differen-
tiation factor 6 (GDF6) oncogene, a BMP factor that is recurrently 
amplified and specifically expressed in melanomas. GDF6, which 
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zebrafish are diverged by 420 million years (21), and the genom-
ic reorganization that has occurred over time has been predict-
ed to frequently place orthologous driver genes next to different 
neighboring genes in each species. Consequently, orthologous 
driver genes would be altered in both species, but changes to 
neighboring passenger genes would be limited to a single spe-
cies. To test this hypothesis, we sought to compare genes that 
are recurrently amplified in human melanomas, roughly 10% 
of the genome (22), to genes recurrently amplified in zebrafish 
melanomas. Using melanomas that arose autochthonously in a 
Tg(mitfa:BRAFV600E);p53(lf) zebrafish strain (23), we performed 
is expressed in the embryonic neural crest, regulates a trunk neural 
crest gene signature in melanomas. Loss of GDF6 results in the dif-
ferentiation and death of melanoma cells, indicating that GDF6 and 
the BMP signaling pathway are required for tumor maintenance and 
are thus potentially important targets in melanoma therapy.
Results
Comparative oncogenomics and expression analyses identify GDF6 
dysregulation in melanoma. We hypothesized that a cross-species 
comparative approach with zebrafish would aid in the identifi-
cation of cancer genes in regions of broad CNVs. Humans and 
Figure 1. GDF6 is recurrently amplified and specifically expressed in melanomas. (A) Circos plot displaying gene copy number gains and losses of 
zebrafish melanomas across 25 chromosomes. JISTIC G-scores are displayed as pale red shading (amplifications [minimum = 0; maximum = 1,550]) and 
blue shading (deletions [minimum = 0; maximum = 2,150]). –log10-transformed JISTIC Q-values with a cutoff of 0.6 (corresponding to an untransformed 
Q-value of 0.25) are shown as bold red lines (amplifications [minimum = 0; maximum = 11]) and bold blue (deletions [minimum = 0; maximum = 11]). 
Dotted circles represent the –log10-transformed Q-value of 0 (center) and 11 (outer: amplification; inner: deletion). (B) Venn diagram of orthologous genes 
significantly amplified in human and zebrafish melanomas from a total of 10,380 human-zebrafish gene pairs (hypergeometric test, P value: 2.0 × 10–15). 
(C) Genes significantly upregulated in zebrafish melanomas as compared with melanocytes (microarray data set) are plotted in order of their fold change. 
Only genes with a fold change of greater than 2 and an adjusted P value of less than 0.05 are plotted. Recurrently amplified genes with amplified human 
orthologs are indicated in red. gdf6b (large red dot) and gdf6a (large black dot) are indicated. Dashed horizontal line represents a fold change of 2. (D) 
Immunostaining of Tg(mitfa:BRAFV600E);p53(lf) zebrafish scales bearing melanoma cells or normal melanocytes. DAPI (blue), Gdf6b (green), Mitfa 
(red), and a merged image of all channels are shown. Mitfa antibody specificity is shown in Supplemental Figure 2B. Scale bars: 10 μm.
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melanoma progression (15, 17, 32), and we were intrigued by the 
notion that a developmental role for GDF6 genes could be reit-
erated to promote melanomagenesis.
GDF6 modulation alters melanoma onset in zebrafish. To assess 
whether GDF6 genes could promote melanoma, we first exam-
ined how their elevated expression affected tumor onset in zebra-
fish. We expressed gdf6a and gdf6b in the melanocyte lineage of 
Tg(mitfa:BRAFV600E);p53(lf);mitfa(lf) zebrafish using the mini-
CoopR system, as previously described (28). The mitfa(lf) muta-
tion prevents melanocyte development and melanoma formation 
in Tg(mitfa:BRAFV600E);p53(lf) fish. When single-cell embryos 
from the Tg(mitfa:BRAFV600E);p53(lf);mitfa(lf) strain were inject-
ed with miniCoopR-EGFP, 21% of these animals later developed 
chimeric rescue of melanocytes. However, in embryos injected 
with miniCoopR-gdf6a or miniCoopR-gdf6b, only,0.6% and 7% of 
injected animals had melanocyte rescue, respectively (Supplemen-
tal Figure 4A). We did not observe this lack of melanocyte rescue 
in control embryos that were injected with miniCoopR vectors 
that had premature stop codons engineered into the gdf6 genes 
(Supplemental Figure 4A). In addition to the low percentages of 
miniCoopR-gdf6a– or miniCoopR-gdf6b –injected embryos that 
showed melanocyte rescue, the embryos that were rescued had 
significantly lower numbers of melanocytes (Supplemental Fig-
ure 4B). Because of this poor rescue, we were only able to perform 
melanomagenesis assays with miniCoopR-gdf6a–injected ani-
mals. When allowed to develop to adulthood, the fish with mela-
nocyte-driven gdf6b expression had accelerated melanoma onset 
(median onset = 13 weeks) as compared with EGFP-expressing 
controls (median onset = 17 weeks) (Figure 2A). Accelerated onset 
was dependent on BRAFV600E and loss of p53, as expression of 
gdf6b in the Tg(mitfa:BRAFV600E) transgene (n = 33) or p53(lf) (n = 
24) backgrounds alone did not produce tumors.
We next assayed the consequences of GDF6 loss in vivo 
using a zebrafish melanoma model. Since gdf6a loss-of-func-
tion animals were previously established (33), we used these 
mutants to test the role of GDF6 loss in melanoma onset. We 
bred a gdf6a loss-of-function, mutation into tumor-prone Tg(mit-
fa:BRAFV600E);p53(lf) zebrafish and found that the resulting 
Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf)–mutant animals had sub-
stantially delayed melanoma onset as compared with their control 
siblings (Figure 2B). Together, these results indicate that GDF6 
ortholog activity is important for melanoma initiation, as overex-
pression of gdf6b caused accelerated tumor onset, whereas loss of 
gdf6a caused a delay in disease onset.
We also found that gdf6a-mutant zebrafish had a profoundly 
altered pigmentation pattern. We observed an increase in melano-
cytes in the flanks of gdf6a-mutant homozygotes, whereas WT sib-
lings had normal pigmentation (Supplemental Figure 4C). Given 
these observations, in combination with our finding that increased 
expression of GDF6 orthologs caused a reduction in the number of 
embryonic melanocytes, we speculate that these genes have a role 
in inhibiting melanocyte development.
GDF6 modulation affects the tumorigenicity of human melano-
ma cells. We next wanted to test whether GDF6 modulation altered 
the growth of human melanoma cells. We first identified cell lines 
with GDF6 amplification (A375, SK-MEL-28, and SK-MEL-5) and 
others without amplification (M14 and C32) (34). Those with 
array comparative genomic hybridization (aCGH) to generate 
CNV profiles (Figure 1A and Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI92513DS1). The Tg(mitfa:BRAFV600E);p53(lf) strain combines 
a transgene that drives expression of human BRAFV600E in the 
melanocyte lineage with a p53 loss-of-function mutation, and 
every animal of this genotype ultimately develops 1 or more mel-
anomas. aCGH values were analyzed with the JISTIC algorithm 
(24) to define recurrently varied intervals, which largely over-
lapped with intervals obtained in an independent study of zebra-
fish melanomas (25). Recurrently amplified genes from JISTIC 
intervals were compared with their human orthologs. The degree 
of overlap between orthologs amplified in both species (374 genes) 
is greater than would be expected by chance (247 genes) (Figure 
1B and Supplemental Table 2), suggesting that amplification of 
similar driver genes mechanistically underlies tumor formation in 
both species. As a further indication of mechanistic conservation, 
known melanoma drivers, including TERT, MYC, and SETDB1, 
were recurrently amplified in both species,(26–28).
Expression analyses were used to further winnow the list of 
candidates. Since copy number–amplified driver genes predom-
inantly act by upregulation of WT transcripts, we obtained tran-
scriptional profiles of zebrafish melanomas and normal mela-
nocytes. Briefly, unpigmented EGFP-positive melanocytes and 
melanoma cells were sorted from the scales and tumors, respec-
tively, of Tg(mitfa:BRAFV600E);p53(lf);Tg(mitfa:EGFP;alb(fl) fish. 
RNA was prepared from each cell population and subjected to both 
microarray analysis and massively parallel RNA sequencing (RNA-
seq). Genes recurrently amplified and transcriptionally upregu-
lated in both species (120 genes; fold change >2, adjusted P value 
< 0.05) included the BMP factor GDF6 (also known as BMP13) 
and its zebrafish ortholog gdf6b (Figure 1, B and C, Supplemental 
Figure 1, A–C and Supplemental Table 3). To determine whether 
Gdf6b protein was similarly enriched in melanomas, we generated 
an antibody that specifically recognizes Gdf6b (Supplemental Fig-
ure 2A). Whereas Gdf6b protein was readily detected in tumor cells 
from Tg(mitfa:BRAFV600E);p53(lf) fish, we did not detect Gdf6b 
in normal melanocytes from these same animals (Figure 1D). 
Human genes often have 2 zebrafish orthologs because of a partial 
genome duplication in the teleost lineage. The second zebrafish 
ortholog of human GDF6, gdf6a, was not recurrently amplified but 
was among the most transcriptionally upregulated genes in mela-
nomas compared with that detected in melanocytes (Figure 1C and 
Supplemental Figure 1B). Together, these data highlight the recur-
rent amplification and tumor-specific expression of GDF6 genes in 
human and zebrafish melanomas.
GDF6 orthologs were particularly interesting, because their 
expression pattern in zebrafish embryos suggested that they 
may regulate melanocyte development. Zebrafish orthologs of 
GDF6 are expressed during neurulation and development of the 
neural crest, the embryonic tissue that gives rise to melanocytes 
(29–31). Using ISH, we confirmed the expression of gdf6a and 
gdf6b in the neural tube and neural crest, respectively. Later in 
development, we found that the expression of these genes was 
absent from differentiating embryonic melanocytes (Supple-
mental Figure 3). Factors involved in neurulation and neural 
crest signaling have been previously implicated in promoting 
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Figure 2. GDF6 modulation alters melanoma growth. (A) Melanoma-free survival curves for Tg(mitfa:BRAFV600E);p53(lf);mitfa(lf) zebrafish injected with 
miniCoopR-gdf6b or miniCoopR-EGFP. Statistical analysis was performed with a Wilcoxon rank-sum test. (B) Melanoma-free survival curves for Tg(mit-
fa:BRAFV600E);p53(lf) and Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) zebrafish. Statistical analysis was performed with a Wilcoxon rank-sum test. (C) Immu-
noblot showing expression and quantification of GDF6 protein levels (relative to GDF6 protein in A375 melanoma cells) in melanoma cell lines. GAPDH was 
used as a loading control. Copy number values of the GDF6 locus in the different melanoma cell lines obtained from the COSMIC database (http://cancer.
sanger.ac.uk/cosmic) are shown. (D) Immunoblots showing expression of GDF6 and GAPDH in A375 melanoma cells and M14 melanoma cells overexpressing 
GDF6. (E) Tumor formation in mice injected with A375 cells and M14 cells overexpressing GDF6 or empty vector control (1 × 106 cells were injected per mouse). 
Error bars represent the mean ± SEM. n = 3. (F) Immunoblots showing expression of GDF6 in A375 cells (top) expressing an shRNA targeting EGFP or 2 
independent GDF6-targeted shRNAs and M14 cells (bottom) expressing an shRNA targeting EGFP or the GDF6-targeted shRNA GDF6.1. (G) Colony formation 
assay with A375 cells (left) expressing an shRNA targeting EGFP or 2 independent GDF6-targeted shRNAs and M14 cells (right) expressing an shRNA target-
ing EGFP or the GDF6-targeted shRNA GDF6.1. Error bars represent the mean ± SEM. n = 3. (H) Tumor formation in mice injected with A375 cells expressing 
an shRNA targeting EGFP or 2 independent GDF6-targeted shRNAs and M14 cells expressing an shRNA targeting EGFP or the GDF6-targeted shRNA GDF6.1 
(1 × 107 cells were injected per mouse). Error bars represent the mean ± SEM. n = 3. *P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed Student’s t test (E and 
G [right] and H [right]) or 1-way ANOVA with Dunnett’s test (G [left] and H [left]).
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we performed ChIP and massively parallel sequencing (ChIP-seq) 
of p-SMAD1/5/8 in control and GDF6-knockdown A375 melano-
ma cells. Binding of p-SMAD1/5/8 to promoter regions of target 
genes was markedly reduced upon GDF6 knockdown (Figure 3E). 
Likewise, in a broader consideration of all p-SMAD1/5/8–bound 
regions, we found that knockdown of GDF6 caused a general reduc-
tion in binding (Supplemental Figure 6A). The reduction in binding 
was, in many cases, accompanied by transcriptional changes; for 
example, reduced binding and transcriptional downregulation 
co-occurred at the well-established p-SMAD1/5/8 target genes ID1 
and ID3 (Supplemental Figure 6, B and C). These results indicate 
that BMP signaling is active in melanomas, and much of this activ-
ity is driven by GDF6.
GDF6 acts via the BMP/SMAD pathway to promote tumor pro-
gression. To test whether the role of GDF6 in promoting melanoma 
progression is mediated by the SMAD1/5/8 axis of BMP signaling, 
we modulated the pathway activity in A375 cells. Knockdown of 
SMAD1 led to defects in cell growth and tumorigenic potential 
(Supplemental Figure 7, A–C), as was observed in GDF6-knock-
down cells. We also used a small-molecule inhibitor of BMP sig-
naling, DMH1, to block pathway activity. DMH1 can suppress the 
growth of BMP-dependent ovarian and lung cancer cells (36, 37), 
but its efficacy in melanoma has not been reported. DMH1 inhib-
its the kinase activity of ALK2 and BMPR1A (ALK3) receptors but 
not of BMPR1B (ALK6), thereby abrogating phosphorylation and 
activation of the SMAD1/5/8 transcriptional cascade (38). GDF6 
has been shown to act through BMPR1A (ALK3) (35), and we 
found that treatment with DMH1 reduced p-SMAD1/5/8 levels 
and decreased cell growth and tumorigenicity (Figure 3F and Sup-
plemental Figure 7, D and E). To test the relationship of GDF6 to 
SMAD1 in genetic epistasis analyses, we expressed a phosphomi-
metic variant of SMAD1, SMAD1DVD, in A375 cells (Supplemental 
Figure 7F) (39). Whereas GDF6 knockdown abrogated cell growth 
and the tumorigenic potential of A375 control cells, A375-SMAD-
1DVD cells subjected to GDF6 knockdown were rescued, showing 
robust growth in colony formation and xenotranplantation assays 
(Figure 3G and Supplemental Figure 7, G and H). The growth 
defects caused by treatment with DMH1 were also reversed by 
SMAD1DVD (Supplemental Figure 7I). Together, these data indi-
cate that GDF6 signals via SMAD-dependent BMP signaling to 
promote tumorigenesis, and inhibition of this signaling achieves a 
reduction in tumor growth.
GDF6-dependent BMP signaling maintains a trunk neural crest 
gene signature. Since GDF6 acts through SMAD transcription fac-
tors, we were interested in identifying gene expression changes 
that could illuminate how this signaling axis regulates tumori-
genesis. To do this, we modulated GDF6 and SMAD1 and sought 
genes commonly regulated by both. Given our genetic epistasis 
results, we predicted that the expression of important genes would 
change upon GDF6 knockdown but that such changes would be 
reversed when GDF6 knockdown was rescued by SMAD1DVD. 
Using RNA-seq, we defined the set of genes that was differentially 
regulated upon GDF6 knockdown and showed reciprocal differ-
ential regulation in SMAD1DVD-expressing cells that were sub-
jected to GDF6 knockdown (Figure 4A and Supplemental Table 
4). Pathway analysis showed that this gene set overlapped most 
significantly with genes involved in ossification and neural crest 
amplification had higher levels of GDF6 protein as compared 
with levels in the nonamplified lines (Figure 2C; see complete 
unedited blots in the supplemental material). We overexpressed 
GDF6 in A375, SK-MEL-28, and M14 melanoma cells (Figure 2D 
and Supplemental Figure 5A), followed by their transplantation 
into immunocompromised mice. In each case, elevation of GDF6 
expression increased the tumor-forming potential of these mel-
anoma cells as compared with the empty vector controls (Figure 
2E and Supplemental Figure 5, B and C). GDF6 overexpression 
also caused an increase in the colony-forming potential of A375 
cells, indicating that it can also enhance the tumorigenic capac-
ity in vitro (Supplemental Figure 5D). These data indicate that 
increased GDF6, regardless of its endogenous levels, can promote 
the tumorigenicity of melanoma cells.
To determine the effects of GDF6 loss, we knocked down 
endogenous GDF6 in melanoma cells with amplifications or normal 
copy number of the GDF6 locus. Knockdown in amplified A375, 
SK-MEL-28, and SK-MEL-5 cells led to a growth disadvantage in 
vitro, as measured by anchorage-dependent colony formation,(Fig-
ure 2, F and G, and Supplemental Figure 5, E and F). In xenografts 
of A375 and SK-MEL-28 cells with GDF6 knockdown, we observed 
a substantial reduction in the tumorigenic potential compared with 
that of control cells with EGFP knockdown (Figure 2H and Supple-
mental Figure 5G). However, knockdown of GDF6 in nonamplified 
M14 and C32 cells caused little change in anchorage-dependent 
colony formation,(Figure 2, F and G, and Supplemental Figure 
5, E and F). In addition, in xenografts, we found no change in the 
tumor-forming potential of M14 cells with GDF6 knockdown com-
pared with that of control M14 cells with EGFP knockdown (Fig-
ure 2H). Therefore, whereas all cells examined showed increased 
tumorigenic potential upon GDF6 overexpression, only cells with 
amplification and higher levels of GDF6 protein were sensitive to 
GDF6 knockdown. These results suggest that GDF6 does not serve 
a housekeeping function, but rather that cells are dependent on its 
amplification and high expression for their tumorigenic potential.
BMP signaling is active in melanomas and is driven by GDF6 
ligand. GDF6 genes, which encode BMP ligands, are predicted to 
act through SMAD1/5/8 transcription factors. For this reason, we 
investigated whether SMAD-dependent signaling was activated in 
melanomas. Using an antibody that specifically recognizes phos-
phorylated SMAD1/5/8 (p-SMAD1/5/8) proteins to monitor BMP 
pathway activity, we found robust p-SMAD1/5/8 nuclear stain-
ing in zebrafish melanomas (Figure 3A). Furthermore, transcrip-
tome analyses of zebrafish melanomas indicated an upregulation 
of genes that support BMP signaling, including the BMPR1A and 
BMPR2 receptor subunits through which GDF6 is known to act (35) 
(Figure 3B). gdf6a and gdf6b were the only BMP ligands found to 
be upregulated in zebrafish melanomas, leading us to hypothesize 
that BMP signaling in melanomas is largely dependent on GDF6 
(Figure 3C). To address this hypothesis, we modulated GDF6 activ-
ity in human melanoma cells. GDF6 knockdown caused a profound 
reduction in p-SMAD1/5/8 levels (Figure 3D), whereas GDF6 over-
expression led to an increase in p-SMAD1/5/8 (Supplemental Fig-
ure 5H). p-SMAD1/5/8 proteins translocate to the nucleus, where, 
in complexes with SMAD4 and/or other regulatory proteins, they 
bind DNA and modulate the transcription of target genes. To deter-
mine whether GDF6 regulates SMAD1/5/8 DNA-binding activity, 
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development (Figure 4B). GDF6-SMAD regulation of neural crest 
genes is intriguing, since melanocytes initially develop from this 
embryonic tissue. Several genes upregulated by GDF6 and SMAD-
1DVD — SOX10, TFAP2B, FOXD3, and SNAI2 — are neural crest 
“specifier” genes that are expressed broadly in the neural crest 
and help to maintain neural crest identity (Figure 4C) (40). SOX9 
is initially broadly expressed in the neural crest, but as develop-
ment proceeds, its expression becomes excluded from the trunk 
Figure 3. GDF6-dependent BMP activity in melanomas. (A) Transverse sections of a Tg(mitfa:BRAFV600E);p53(lf) zebrafish bearing an invasive melanoma in the 
dorsal musculature. Top: H&E staining; bottom: p-SMAD1/5/8 staining. Scale bars: 500 μm (left) and 50 μm (enlarged insets on right). For p-SMAD1/5/8 staining, 
normal muscle (top) and a tumor region (bottom) are shown. Note that normal scale tissue (running vertically through the middle of the image) in the tumor 
region is p-SMAD1/5/8 negative. T, tumor; N, normal. (B) Heatmap of expression of BMP pathway genes (Reactome gene set R-HSA-201451.3; https://reactome.
org/PathwayBrowser/) in zebrafish melanomas as compared with expression in melanocytes. Human orthologs of zebrafish genes are shown. (C) log2-trans-
formed fold change of gene expression in zebrafish melanomas as compared with expression in melanocytes (y axis). Expression of BMP ligands in microarray 
analysis and RNA-seq analysis. Only BMP ligands with a significant dysregulation (adjusted P < 0.05) are shown. (D) Immunoblots of p-SMAD1/5/8 and total 
SMAD1/5/8 in A375 melanoma cells expressing an shRNA targeting EGFP or 2 independent GDF6-targeted shRNAs. (E) Aggregation plot of p-SMAD1/5/8 
ChIP-seq enrichment at annotated transcriptional start sites (TSSs) in A375 melanoma cells expressing an shRNA targeting EGFP or the GDF6-targeted shRNA 
GDF6.1. The P value was calculated by 2-sample Kolmogorov-Smirnov (K-S) test after summing TSS proximal reads (–2kb to 2kb) for each gene (n = 49,344 TSSs). 
RPM, reads per million. (F) Tumor formation in mice injected with A375 cells (1 × 106 cells injected per mouse) treated with vehicle control or 25 mg/kg DMH1 every 
other day. Error bars represent the mean ± SEM. n = 8. (G) Tumor formation in mice injected with A375 empty or A375-SMAD1DVD cells expressing 2 independent 
GDF6-targeted shRNAs. Each mouse was injected with 1 × 107 cells. Error bars represent the mean ± SEM. n = 3. **P < 0.01 and ***P < 0.001, by 2-tailed Student’s 
t test (F) or 1-way ANOVA with Bonferroni’s test (G).
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neural crest and limited to the cranial neural crest, from which 
mesenchymal tissues such as craniofacial cartilage are derived. 
Conversely, SOX10 expression becomes restricted to the trunk 
neural crest from which nonmesenchymal cells, including mela-
nocytes, develop. Since SOX10 is upregulated and SOX9 is down-
regulated by GDF6/SMAD signaling, the pattern of gene regula-
tion most closely resembles trunk neural crest tissue. Adopting a 
neural crest–like identity can contribute to the aggressive nature 
of melanoma cells (16, 41). For these reasons, we hypothesized 
that GDF6-driven BMP signaling (GDF6/SMAD), by promoting 
a trunk neural crest gene signature, enables melanoma cells to 
adopt and maintain an undifferentiated, protumorigenic state.
GDF6 inhibits melanoma cell differentiation by repressing MITF. 
To determine how GDF6-driven BMP signaling could regulate the 
differentiation of melanoma cells, we considered target genes that 
were bound by p-SMAD1/5/8 and transcriptionally regulated in 
a GDF6-dependent manner. Among these genes was MITF, the 
master regulator of melanocyte differentiation. In control A375 
cells, we detected p-SMAD1/5/8 binding in the MITF locus in a 
region that is intronic for longer MITF isoforms and upstream of 
the smaller MITF-M isoform, the predominant species of MITF 
in melanocytes and melanomas (Figure 5A) (42). Binding to this 
region was abrogated in GDF6-knockdown cells. This loss of 
binding in GDF6-knockdown melanoma cells was coupled with a 
transcriptional increase in MITF (Figure 5B). MITF itself is a tran-
scriptional factor that orchestrates differentiation, in part, by acti-
vating the expression of melanin biosynthesis genes. The increase 
in MITF upon GDF6 knockdown was accompanied by an increase 
in,the melanin biosynthesis gene TRP1 (Figure 5C), indicating that 
melanocyte differentiation was invoked upon GDF6 loss. Upregu-
lation of MITF and TRP1 was less pronounced when GDF6 knock-
down was performed in SMAD1DVD-expressing cells (Figure 5, B 
and C). Depending on the cofactors involved, p-SMAD1/5/8 can 
promote transcription, as with ID1 and ID3, or repress transcrip-
tion, as we propose for MITF (43). To determine whether GDF6 
regulates the differentiation of melanomas in vivo, we exam-
ined tumors that arose in Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) 
zebrafish. Melanomas from these animals had increased tran-
script levels of mitfa and trp1b, which are orthologs of the human 
MITF and TRP1 genes (Figure 5D). Furthermore, gdf6a-mutant 
tumors showed a profound increase in melanization as compared 
with control tumors (Figure 5E). These results show that GDF6 
maintains melanomas in an undifferentiated state, and we spec-
ulate that preventing differentiation helps melanoma cells retain 
a neural crest identity.
GDF6 represses SOX9 to promote melanoma cell survival. 
Knockdown of GDF6 and SMAD1 caused defects in melanoma 
cell growth. We sought to understand this defect and whether 
the trunk neural crest signature was involved. A variety of analy-
ses suggested that the growth defect was linked to the regulation 
of apoptosis. Specifically, gene set enrichment analysis (GSEA) 
revealed that GDF6 expression was negatively correlated with 
expression of apoptotic pathway genes in cells with GDF6 modu-
lation as well as in patients’ samples (Figure 6A and Supplemental 
Figure 8, A and B). In direct assessments, we found that GDF6 loss 
increased apoptotic cell death in A375 cells as well as in vivo in 
zebrafish melanomas and mouse xenografts (Figure 6, B and C, 
and Supplemental Figure 8, C–E). By contrast, GDF6 overexpres-
sion xenografts showed reduced apoptotic cell death as compared 
with basal levels of cell death in control xenografts (Supplemental 
Figure 8, F and G). GDF6 overexpression xenografts had a slightly 
increased Ki67-proliferative index, suggesting that the reduction 
in cell death was not caused by a failure to generate new cells with 
the potential to die (Supplemental Figure 8H). Finally, the cell 
death caused by GDF6 knockdown was rescued by SMAD1DVD 
expression, indicating that GDF6 acts via BMP signaling to pro-
mote melanoma cell survival (Figure 6D and Supplemental Figure 
9). The involvement of GDF6 in cell death is consistent with find-
ings in which loss of GDF6 orthologs in fish and Xenopus caused 
a substantial increase in apoptosis during eye and neural devel-
opment (44–46). We speculate that GDF6 knockdown causes ter-
minal differentiation of melanoma cells, leading to cell-cycle exit 
followed by cell death.
To determine how GDF6 and BMP signaling regulate melano-
ma cell survival, we focused on the reciprocally regulated genes 
defined previously. In particular, SNAI2 and SOX9 were assessed 
because of their importance in specifying neural crest and regu-
lating cell survival (47–50). Whereas modulation of SNAI2 had no 
effect on GDF6-driven survival (Supplemental Figure 10), SOX9 
was intimately involved. In studying SOX9, we first confirmed 
that changes in GDF6 and BMP signaling affected SOX9 expres-
sion. A375 cells with GDF6 knockdown had increased SOX9 RNA 
Figure 4. GDF6 and SMAD1 regulate a neural crest gene signature in melanomas. (A) Genes differentially regulated in A375 melanoma cells upon GDF6 
knockdown (KD) (purple circle) and genes reciprocally regulated in SMAD1DVD-expressing A375 cells upon GDF6 knockdown (green circle). (B) Pathway 
analysis with the 605 reciprocally regulated genes (minimum overlap ≥10 genes; adjusted P < 0.01). Wikipathway analysis was done using Webgestalt 
toolkit (http://www.webgestalt.org/webgestalt_2013/). (C) Heatmap of neural crest genes identified in the pathway analysis.
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patients’ samples detected high levels of GDF6 protein in mela-
nomas; however, normal melanocytes from adjacent skin (Figure 
7A) or tumor-infiltrating cells (Supplemental Figure 12) rarely 
expressed GDF6. In the same cohort, we found high BMP pathway 
activity, as measured by nuclear p-SMAD1/5/8 staining, in tumor 
cells but not in normal tissue (Figure 7A and Supplemental Figure 
12). To determine whether expression of GDF6 correlated with 
the clinical characteristics of melanoma patients, we performed 
IHC on a microarray with 104 melanoma tissue cores (78 primary 
and 26 metastatic melanomas). Consistent with the initial cohort, 
we observed robust GDF6 expression in a majority of melanomas 
(80% of total; n = 104 cases). Importantly, in analyzing clinical 
aspects of the melanoma tissue microarray, we found that patients 
whose tumors at diagnosis expressed high amounts of GDF6 had a 
lower survival probability than did those whose tumors expressed 
no or low GDF6 (Figure 7B and Supplemental Table 5). This asso-
ciation was mainly driven by patients with primary melanomas 
(Supplemental Figure 13A). Additionally, GDF6 expression in 
primary melanomas significantly correlated with lymph node 
metastasis (Figure 7C). In these primary melanomas, expression 
of GDF6 tended to be higher than in metastatic lesions (Supple-
mental Figure 13B). Together, these data indicate that GDF6 is a 
negative prognostic marker for early-stage melanomas.
and protein levels, and this increase was much less pronounced in 
SMAD1DVD cells that were subjected to GDF6 knockdown (Fig-
ure 6E and Supplemental Figure 11A). Additionally, gdf6a-mutant 
zebrafish melanomas showed elevated sox9b levels (Supplemen-
tal Figure 11B). To determine whether GDF6 mediates cell survival 
by regulating SOX9, we measured whether knockdown of SOX9 
(Supplemental Figure 11, C and D) could suppress the growth 
defects and cell death resulting from GDF6 knockdown. In colony 
formation assays, cells with combined knockdown of SOX9 and 
GDF6 grew much better than did GDF6 single-knockdown cells 
(Supplemental Figure 11E). Similarly, cell death, as measured by 
caspase-3 cleavage and annexin V positivity, was greatly reduced 
in GDF6/SOX9 double-knockdown cells (Figure 6F and Supple-
mental Figure 11F). Last, we measured the ability of SOX9 knock-
down to rescue the tumor-forming capacity of GDF6-knockdown 
cells. When performed together with GDF6 knockdown, SOX9 
knockdown enabled cells to engraft and rapidly grow (Figure 6G  
and Supplemental Figure 11G). These data indicate that a major 
function of GDF6 is to repress SOX9 expression, thereby inhibit-
ing cell death and promoting tumor growth.
Clinical significance of GDF6 expression and signaling. We next 
assessed the expression of GDF6 in human melanomas and exam-
ined the potential clinical implications. IHC on an initial cohort of 
Figure 5. GDF6-induced BMP signaling blocks melanoma cell differentiation. 
(A) p-SMAD1/5/8 binding to the MITF locus in A375 melanoma cells expressing 
an shRNA targeting EGFP or the GDF6-targeted shRNA GDF6.1. Traces of 2 inde-
pendent biological replicates are shown. (B) qRT-PCR analysis showing expression 
of MITF in A375 empty or A375-SMAD1DVD cells expressing an shRNA targeting 
EGFP or the GDF6-targeted shRNA GDF6.1. (C) qRT-PCR analysis of TRP1 under the 
same conditions. Left brackets: MITF or TRP1 expression was upregulated upon 
GDF6 knockdown. Right brackets, MITF or TRP1 expression was less upregulated in 
SMAD1DVD-expressing cells upon GDF6 knockdown. Error bars represent the mean 
± SEM. n = 3. (D) qRT-PCR analysis showing expression of mitfa and trp1b in control 
and gdf6a(lf) zebrafish melanomas. Error bars represent the mean ± SEM. n = 3. 
(E) H&E staining of transverse sections from Tg(mitfa:BRAFV600E);p53(lf) and 
Tg(mitfa:BRAFV600E);p53(lf);gdf6a(lf) zebrafish melanomas invading the dorsal 
musculature. Scale bars: 100 μm (left) and 25 μm (right). *P < 0.05 and ***P < 0.001, 
by 1-way ANOVA with Bonferroni’s test (B and C) or 2-tailed Student’s t test (D).
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ments (compare Figure 2H and Figure 3F). These results indicate 
that targeting GDF6-driven BMP signaling, in combination with 
current therapeutic strategies, may have profound clinical benefits.
Discussion
The genomic and functional analyses performed in this study 
identified GDF6 as a melanoma oncogene. The results of these 
and additional mechanistic studies allowed us to develop a mod-
el for the role of GDF6 in melanoma tumorigenesis (Figure 7E). 
Next, we wanted to test whether targeting GDF6-driven BMP 
signaling could be combined with existing therapies. We treated 
established A375 melanoma xenografts with DMH1 or dabrafenib 
plus trametinib or a combination of all 3 drugs. While treatment 
with dabrafenib plus trametinib caused substantial regression, the 
combination of DMH1 with dabrafenib and trametinib showed even 
further regression (Figure 7D). Treatment with DMH1 alone had lit-
tle effect, although we presume that it does not fully inhibit GDF6- 
driven BMP signaling in vivo, as indicated by our previous experi-
Figure 6. GDF6 and BMP signaling repress SOX9 to 
promote melanoma cell survival. (A) GSEA showed 
that expression of an apoptotic gene set (MSigDB 
M10169) was negatively enriched in GDF6-over-
expressing A375 cells. (B) Caspase-3/7 activity 
measured as relative luciferase units (RLU) in A375 
cells upon GDF6 knockdown. Error bars represent the 
mean ± SEM. n = 3. (C) Fluorescent TUNEL staining 
of Tg(mitfa:BRAFV600E);p53(lf) (top) or Tg(mit-
fa:BRAFV600E);p53(lf);gdf6a(lf) (bottom) zebrafish 
melanoma sections. TUNEL (green), DAPI (blue), and 
a merged image of both channels are shown. Scale 
bars: 25 μm. Error bars represent the mean ± SEM.  
n = 100 fields. (D) TUNEL staining of mouse 
xenografts of A375 cells expressing SMAD1DVD 
upon GDF6 knockdown. Scale bar: 25 μm. Error bars 
represent the mean ± SEM. n = 100 fields. (E) Immu-
noblots showing expression of SOX9 and GAPDH in 
A375 empty or A375-SMAD1DVD cells expressing an 
shRNA targeting EGFP or the GDF6-targeted shRNA 
GDF6.1. (F) Caspase-3/7 activity measured as relative 
luciferase units (RLU) in A375-nonsilencing or A375-
shSOX9 cells expressing an shRNA targeting EGFP 
or the GDF6-targeted shRNA GDF6.1. Error bars repre-
sent the mean ± SEM. n = 3. (G) Tumor formation 
in mice injected with A375-nonsilencing or A375-
shSOX9 cells expressing 2 independent GDF6-tar-
geted shRNAs. Each mouse was injected with 1 × 106 
cells. Error bars represent the mean ± SEM. n = 3. 
***P < 0.001, by 1-way ANOVA with Dunnett’s test 
(B), 2-tailed Student’s t test (C), or 1-way ANOVA 
with Bonferroni’s test (D, F, and G). ###P< 0.001, by 
1-way ANOVA (G).
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crest characteristics are proposed to be instrumental in melanoma 
initiation. Given that GDF6 and its orthologs are melanoma onco-
genes that promote a neural crest gene signature, we speculate 
that GDF6 and BMP signaling are important at the earliest stages 
of melanoma formation.
Reiteration of embryonic GDF6 activities in melanomas. GDF6 is 
expressed during embryogenesis, and its functions during devel-
opment mirror those upon its reactivation in melanomas. In Xeno-
pus and zebrafish embryos, GDF6 is expressed at the edges of the 
neural plate and in the eye fields of the anterior neural plate. Upon 
neural tube closure, expression is prominent in the dorsal neural 
tube and neural crest (29, 31, 45). Loss-of-function studies in both 
species suggest that GDF6 promotes ectodermal cell survival (45, 
58). In Xenopus and zebrafish, knockdown of GDF6 and gdf6a, 
respectively, caused a reduction in eye size that resulted from 
inappropriate death of retinal neuron progenitor cells (44, 46, 59). 
GDF6 also acts during embryogenesis to regulate cell differentia-
tion. In the mouse, Gdf6 inhibits differentiation of the mesenchy-
mal progenitors that develop into the coronal suture, and preco-
cious differentiation of these cells results in fusion (60, 61). Thus, 
in certain tissues, GDF6 can promote cell survival during develop-
ment as well as regulate terminal differentiation.
We have found that GDF6 promotes a neural crest signature 
in melanoma cells. In particular, GDF6 maintains expression of 
the trunk neural crest factor SOX10, while repressing the cranial 
neural crest factor SOX9. Some data support a similar function 
for GDF6 in embryogenesis. As noted above, GDF6 orthologs in 
Xenopus and zebrafish are expressed in the neural crest and adja-
cent dorsal neural tube. In zebrafish, knockdown of gdf6a reduc-
es expression of sox10 in neural crest cells (31), consistent with a 
function in maintaining a trunk neural crest gene signature. As 
development proceeds, gdf6 paralog expression is progressively 
lost in a rostrocaudal direction, which occurs concomitantly with 
rostrocaudal differentiation of crest cells, including melanocytes. 
Perhaps the loss of gdf6 expression removes a barrier to melano-
cyte differentiation. Support for such a barrier has been shown 
in avian embryos, where BMP4-driven pathway activity inhibits 
melanocyte fate specification during neural crest lineage segre-
gation (62). We speculate that GDF6 may activate BMP signaling 
in the neural crest to repress MITF. With MITF repressed, neural 
crest cells can remain undifferentiated and responsive to prolifer-
ative signals as well as those that specify alternative cell fates. In 
melanomas, BMP signaling likewise could promote a neural crest 
cell identity that is not terminally differentiated and therefore 
conducive to proliferation.
Targeting GDF6 and BMP signaling in melanoma. Our patient 
cohort analyses show that a major fraction of melanomas express 
GDF6 and have an active BMP pathway. Since GDF6 expression 
is correlated with poor patient survival, and inhibition of GDF6 
leads to cell death, targeting this gene or the BMP pathway may 
prove to be an effective therapeutic intervention for melanomas. 
GDF6 itself is an attractive target, since its expression is very 
low or undetectable in most adult tissues (63). The knockout of 
mouse Gdf6 indicates that it is a nonessential gene, although it is 
necessary for the development of certain joints, ligaments, and 
cartilage (61). These developmental activities of GDF6 would 
likely not complicate the treatment of adult patients with anti-
First, during the course of melanomagenesis, the GDF6 locus is 
transcriptionally activated, in some cases stemming from copy 
number amplification. The production of GDF6 protein then 
leads to either autocrine or paracrine activation of BMP pathway 
signaling in nascent melanoma cells. Next, BMP signaling trig-
gers SMAD1/5/8-dependent downregulation of MITF and SOX9, 
which inhibits melanoma cell differentiation and death, respec-
tively. GDF6-dependent binding of SMAD1/5/8 to the MITF locus 
suggests that the downregulation in this case is direct. There are 
no SMAD1/5/8-bound regions in the SOX9 locus, so its downreg-
ulation is either indirect or mediated by long-range interactions 
with SMAD1/5/8 that is bound, in a GDF6-dependent fashion, to 
sites in neighboring loci. The outcome of this signaling is to pro-
mote a neural crest gene signature within melanoma cells, which 
enables tumor progression.
GDF6 and BMP signaling in melanoma maintenance and initia-
tion. BMP pathway activity has previously been implicated in mel-
anoma progression. BMP4 and BMP7 expression has been shown 
to promote tumor cell invasion and migration in an autocrine fash-
ion (51), whereas BMP2 and BMP4 promote angiogenesis through 
paracrine signaling (52). Independent studies indicate that BMP7 
can block melanoma cell growth and inhibit metastasis (53, 54), 
suggesting that the effects of BMP7 on melanoma progression may 
be complex and potentially cell line specific. More relevant to our 
studies, BMP signaling has been proposed to promote melanoma 
survival by inducing the antiapoptotic factor DIDO1 (55). We test-
ed whether DIDO1 is involved in the antiapoptotic role of GDF6 
in melanoma cells. Upon GDF6 knockdown, we did not observe 
changes in DIDO1 transcript levels. Furthermore, we found that 
while p-SMAD1/5/8 bound to a site within the DIDO1 gene, this 
site was not differentially bound upon GDF6 knockdown. Thus 
GDF6, via SOX9, likely interfaces with the cell death machinery 
through other factors.
Along with preventing cell death, our studies indicate that GDF6 
and BMP signaling promote melanoma maintenance through addi-
tional mechanisms. GDF6 downregulates the expression of MITF, 
which is likely accomplished by induction of p-SMAD1/5/8 and its 
direct binding to the MITF gene. MITF is a master regulator of the 
melanocyte lineage, and its regulation is critically important for the 
behaviors of cells within this lineage. MITF expression is governed 
by a variety of signals that ultimately produce an expression level 
that dictates cellular phenotype. In this way, MITF is proposed to 
act as a rheostat (41, 56, 57). Specifically, high levels of MITF pro-
mote cell-cycle arrest and terminal differentiation, whereas lower 
expression levels stimulate proliferation. Even lower levels endow 
cells with stem cell–like and invasive properties. We speculate that 
by repressing MITF, GDF6 and BMP signaling keep MITF expres-
sion in a range that not only inhibits terminal differentiation but 
also protects against cell death and endows cells with properties 
important for tumor maintenance.
Our data also implicate GDF6 and BMP signaling in mel-
anoma initiation. In zebrafish, cells in the melanocyte lineage 
that expressed gdf6b gave rise to melanomas more rapidly than 
did control cells. Furthermore, melanoma onset was delayed in 
gdf6a-mutant zebrafish. Recently, it was shown that cells of origin 
for zebrafish melanomas adopt neural crest characteristics that 
distinguish them from normal melanocytes (32). These neural 
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Figure 7. Clinical impact of GDF6 
expression and BMP pathway inhi-
bition. (A) H&E, cytoplasmic GDF6, 
and nuclear p-SMAD1/5/8 immu-
nostaining of adjacent normal skin 
and melanoma tissue from the same 
section. Melanocytes in normal skin 
sections are indicated by arrowheads. 
Images of individual cells are shown 
immediately to the right. Scale bars: 
25 μm. Original magnification: ×63. 
Graphs indicate the percentage of 
patients’ samples with no or low 
expression or high expression of 
these proteins in normal melanocytes 
and melanomas. (B) Left, percent-
age of patients’ samples with no or 
low or high GDF6 expression in the 
melanoma tissue microarray. Graph 
of Kaplan-Meier analysis for the 
melanoma tissue microarray samples 
shows the overall survival of patients 
with no or low GDF6 expression (blue 
line) versus those with high GDF6 
expression (red line). Statistical anal-
ysis was performed with a Mantel-Cox 
log-rank test. (C) GDF6 staining score 
in patients with primary melanomas 
with (n = 61) or without (n = 19) lymph 
node (LN) metastasis. **P < 0.01, by 
2-tailed Welch’s test. (D) Mice bearing 
A375 xenografts were treated with 
vehicle, DMH1, dabrafenib plus trame-
tinib, or a combination of all 3 drugs. 
Normalized tumor volumes following 
the beginning of drug treatments are 
shown. Error bars represent the mean 
± SEM. n ≥ 8 animals. (E) Model for 
GDF6 activation and function in mel-
anomas. **P < 0.01, by 1-way ANOVA 
with Bonferroni’s test (D); ##P < 0.001 
by 1-way ANOVA (D).
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silencing shRNA. The viral dosage was determined such that 100% 
of the cells were EGFP positive and therefore contained the pGIPZ 
vector expressing either SOX9 or nonsilencing shRNA. For transgene 
expression, we used Gateway cloning (Life Technologies, Thermo 
Fisher Scientific) to insert the GDF6 or SNAI2 ORF (GE Life Scienc-
es) or the SMAD1DVD ORF (provided by Takenobu Katagiri, Saitama 
Medical University, Saitama, Japan) into the pLenti CMV Hygro DEST 
(w117-1) vector (provided by Paul Kaufman, UMMS, Worcester, Mas-
sachusetts, USA). Infection and monitoring was performed as previ-
ously described (28), except that selection was done with 300 ug/ml 
hygromycin for 10 days.
Mouse xenografts. A375 cells stably expressing an EGFP, GDF6, 
or SMAD1 shRNA and/or an empty vector or a GDF6-expressing or 
SMAD1DVD-overexpressing vector were s.c. injected into the flanks 
of 6- to 8-week-old BALB/c nu/nu female mice (Taconic Farms) to 
produce orthotopic primary tumors. Primary tumor growth was mon-
itored every 3 days with calipers, and tumor volume was calculated as 
described previously (68). For GDF6 knockdown, SMAD1 knockdown, 
and epistasis experiments with SMAD1DVD overexpression, 1 × 107 
live cells were injected. For GDF6 overexpression experiments and 
epistasis experiments with SOX9 knockdown, 1 × 106 live cells were 
injected. For GDF6 overexpression and GDF6 knockdowns, a repre-
sentative result of 2 independent experiments (n = 3 animals per exper-
iment) is shown. For the DMH1 drug experiments shown in Figure 3F, 
1 × 106 live A375 cells were s.c. injected into the flanks of BALB/c nu/
nu female mice. Beginning on the day cells were injected, mice were 
injected i.p. with vehicle (12.5% 2-hydroxypropyl-β-cyclodextrin) or 25 
mg/kg DMH1 in vehicle every other day. This experiment was repeat-
ed twice, and the weighted average of both experiments (n = 8 animals 
total) is represented. For the drug experiments depicted in Figure 7D, 
1 × 106 A375 cells were s.c. injected into the flanks of BALB/c nu/nu 
female mice. Once the tumor volumes reached 75 mm3, the groups of 
mice were treated with vehicle, DMH1, dabrafenib plus trametinib, or a 
combination of all 3 drugs. DMH1 was administered i.p. in 7-day cycles, 
with 25 mg/kg given twice a day for 5 days and once a day for 2 days. 
Dabrafenib (300 mg/kg) plus trametinib (0.3 mg/kg) were adminis-
tered by oral gavage once per day. The control group received the vehi-
cle 12.5% 2-hydroxypropyl-β-cyclodextrin i.p. in 7-day cycles, with 25 
mg/kg given twice a day for 5 days and once a day for 2 days. Control 
animals also received 0.5% hydroxypropyl methylcellulose once a day 
by oral gavage. These treatment regimens were continued until the end 
of the study or until tumors reached 400 mm3 in size. Eight or nine ani-
mals were used in each group.
Zebrafish stocks and husbandry. Zebrafish were maintained at 28.5°C 
with a 14-hour on/10-hour off light cycle. Tg(mitfa:BRAFV600E) (23), 
p53(lf) (69), mitfa(lf) (70), and gdf6a(lf) (33) zebrafish strains were used. 
gdf6a(lf) mutants were provided by Herwig Baier (Max Plank Institute 
of Neurobiology, Martinsried, Germany). AB was used as the WT strain.
miniCoopR assay. The miniCoopR assay measuring the effect of 
gdf6b on melanoma onset in zebrafish was performed as previously 
described (28). For miniCoopR-EGFP experiments, a weighted aver-
age of 2 independent experiments is represented, and for mini CoopR-
gdf6b experiments, a weighted average of 4 independent experiments 
is represented. For the embryonic melanocyte rescue analysis, embry-
os were treated with epinephrine (1 mg/ml) 4 days after fertilization 
to contract pigment to distinguish any overlapping cells, and melano-
cytes were counted manually.
GDF6 therapy, although it is not known whether GDF6 inhibi-
tion would affect the limited repair of connective tissues that 
occurs in adults. On the other hand, BMP signaling regulates the 
function or repair of some adult tissues, including muscle, bone, 
and lung (64–66). Thus, GDF6 inhibition could be more specif-
ic to melanoma tissue as compared with a broad BMP pathway 
inhibitor such as DMH1, which would block BMP signaling in 
normal tissues. As a secreted molecule, GDF6 inhibition could 
be accomplished by a variety of means, including cell-imperme-
able therapies. Such therapies could be used in different molecu-
lar subtypes of melanoma, as cell death caused by GDF6 inhibi-
tion does not depend on underlying BRAF, NRAS, or other driver 
mutations. Our data do suggest that tumors expressing high lev-
els of GDF6 would be particularly sensitive to GDF6 inhibition. 
This elevated expression correlates with GDF6 gene amplifica-
tion, which is present in 38% of melanomas (67). However, 80% 
of the melanomas we analyzed showed high GDF6 expression, 
suggesting that mechanisms other than amplification can lead 
to higher expression. Ultimately, it would be useful to determine 
whether the level of GDF6 expression is predictive of therapeutic 
response to a GDF6 or BMP inhibitor. As indicated by the potent 
activity against xenografts of DMH1 with dabrafenib plus trame-
tinib, such an inhibitor treatment could be used in conjunction 
with BRAF inhibitors and other MAPK pathway inhibitors to 
treat this lethal disease.
Methods
Additional methods are described in the Supplemental Methods.
Cell lines and cell culture. A375, M14, C32, and HEK293T cells 
(ATCC) were maintained in DMEM, and SK-MEL-28 and SK-MEL-5 
cells (ATCC) were maintained in RPMI 1640 media supplemented 
with 10% FBS and 2 μg/ml penicillin-streptomycin (Gibco, Thermo 
Fisher Scientific) at 37°C and 5% CO2. Cells cultured at the same time 
were pooled, counted, and then seeded in a 10-cm dish. Wells and 
dishes were then subjected to treatment with lentiviral vectors.
Lentiviral infection. Lentiviral infections were performed as 
described previously (28). For stable gene knockdowns, we used pLKO-1 
lentiviral vectors to deliver shRNAs (obtained from the RNAi Con-
sortium [TRC]/Broad Institute through the UMMS RNAi core facili-
ty) specific for GDF6 (GDF6.1, TRCN0000141818, target sequence: 
GCCAAGTGTTACATTGAGCTT; GDF6.2, TRCN0000140097, 
target sequence: GTGTCCATGCTCTCAGACAAA) or SMAD1 
(SMAD1.1, TRCN0000021781, target sequence: CGGTTGCTTAT-
GAGGAACCAA; SMAD1.2, TRCN0000021782, target sequence: 
GCCGATGGACACAAACATGAT) or EGFP (TRCN0000072181, 
target sequence: ACAACAGCCACAACGTCTATA). Virus was made 
using a second-generation lentiviral packaging system in HEK293T 
cells and quantified using a p24 ELISA Kit (Clontech). Cells were 
infected with virus at a MOI of 2.5, with 8 μg/ml polybrene followed 
by puromycin selection (2 μg/ml) for 2 days in appropriate media. 
For genetic epistasis experiments with SOX9, we used the pGIPZ 
lentiviral vectors (obtained from Thermo Fisher Scientific through 
the UMMS RNAi Core facility) to deliver shRNAs specific for SOX9 
(V3LHS_396212, target sequence: AGTCGTACTGTGAGCGGGT) or 
used the nonsilencing control (target sequence: CTTACTCTCGC-
CCAAGCGAGAG). A375 melanoma cells expressing an shRNA tar-
geting GDF6 or EGFP were treated with virus delivering SOX9 or non-
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Accession information. The RNA-seq, ChIP-seq, and gene 
expression microarray data sets reported in this article were depos-
ited in the NCBI’s Gene Expression Omnibus (GEO) database 
(GEO GSE83400).
Statistics. Data are presented as the mean ± SEM. Differences 
between groups were assessed by a 2-tailed Student’s t test, except 
in Figure 2, G and H (left), Figure 3G, Figure 5, B and C, Figure 6, 
B, D, F, and G, Figure 7D, Supplemental Figure 4, A and B, Supple-
mental Figure 6C, Supplemental Figure 7, B, G, and I, Supplemental 
Figure 8C, Supplemental Figure 9, A, B, and C, Supplemental Figure 
10, A–D, and Supplemental Figure 11, A, C, E, and F, where 1-way 
ANOVA was used (GraphPad Prism 7; GraphPad Software). In Fig-
ure 7C, Supplemental Figure 1C, and Supplemental Figure 13B, a 
2-tailed Welch’s t test was used (GraphPad Prism 7). In Figure 3E, 
a 2-sample Kolmogorov-Smirnov test was used. In Figure 1C, Fig-
ure 3C, Figure 4A, Figure 6A, and Supplemental Figure 8, A and B, 
a FWER P value was used to account for multiple comparisons. For 
multiple comparisons, a Dunnett’s or Bonferroni’s test was used as 
appropriate. Kaplan-Meier curves were generated using GraphPad 
Prism 7 (GraphPad Software), and the differences between groups 
were assessed by Wilcoxon rank-sum analysis for Figure 2, A and H, 
and by Mantel-Cox log-rank analysis for Figure 7B and Supplemental 
Figure 12. A P value of less than 0.05 was considered significant.
Study approval. All zebrafish and mouse study protocols were 
approved by the IACUC at UMMS. Approval for the tissue microar-
ray study was granted by the Brigham and Women’s Partners Human 
Research Committee. Informed consent was not necessary, as all tis-
sue samples were discardable and deidentified.
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cDNA synthesis and qRT-PCR. For adult zebrafish, total RNA 
was extracted from melanoma cells and from normal scale-asso-
ciated melanocytes of Tg(mitfa:BRAFV600E);p53(lf);alb(lf);Tg(mit-
fa:EGFP) zebrafish. For isolation of melanoma cells, melanomas 
were dissected, dissociated using Liberase TH treatment (Milli-
poreSigma), and subjected to FACS to isolate EGFP-positive cells. 
The same protocol was used for normal melanocytes, except dorsal 
scales from zebrafish were plucked to isolate melanocytes. Total 
RNA from zebrafish melanomas and melanocytes was isolated using 
TRIzol-chloroform extraction, followed by RNA clean-up using an 
RNeasy Kit (QIAGEN). Total RNA was reverse transcribed using the 
Superscript 2 Reverse Transcriptase Kit (Invitrogen, Thermo Fish-
er Scientific). Quantitative reverse transcription PCR (qRT-PCR) 
with SYBR Green Master Mix (Bio-Rad) was performed using the 
following primers: gdf6a, forward, CTGAGAAACTGGGGCTCAAT; 
gdf6a, reverse, CGACCAGCTCCTCTTTGTCT; gdf6b, forward, 
CGTCTAAAGCAGCAAACACC; gdf6b, reverse, CCAAAGTGGA-
GAGTTCAAATGG; actb1, forward, CGAGCAGGAGATGGGAACC; 
actb1, reverse, CAACGGAAACGCTCATTGC. qRT-PCR was per-
formed using the following primers: mitfa, forward, CTGGACCAT-
GTGGCAAGTTT, mitfa, reverse, GAGGTTGTGGTTGTCCTTCT; 
tyrp1b, forward, CGACAACCTGGGATACACCT, tyrp1b, reverse, 
AACCAGCACCACTGCAACTA.
For A375 human melanoma cells with GDF6 and/or SMAD-
1DVD modulation, total RNA was prepared in the same manner, 
and qRT-PCR was performed using the following primers: ID1, for-
ward, CCAACGCGCCTCGCCGGATC; ID1, reverse, CTCCTCGC-
CAGTGCCTCAG; ID3, forward, CTGGACGACATGAACCACTG; 
ID3, reverse, GTAGTCGATGACGCGCTGTA; SNAI2, forward, 
TGTTGCAGTGAGGGCAAGAA; SNAI2, reverse, GACCCTG-
GTTGCTTCAAGGA; SOX9, forward, GTACCCGCACTTGCA-
CAAC; SOX9, reverse, TCTCGCTCTCGTTCAGAAGTC; MITF, 
forward, AAACCCCACCAAGTACCACA; MITF, reverse, ACATGG-
CAAGCTCAGGAC; TRP1, forward, GTAACAGCACCGAGGATGG; 
TRP1, reverse, TCCAAGCACTGAGCGACAT; GAPDH, forward, 
TGCACCACCAACTGCTTAGC; GAPDH, reverse, GGCATGGACT-
GTGGTCATGAG.
GSEA and pathway analysis. For GSEA, the enrichment score 
(ES), normalized enrichment score (NES), and FWER were calculat-
ed on the basis of a running metric, which increased when a gene 
(vertical line in the graphical representation) in the gene set was 
encountered and decreased when one was not. For GSEA of the 
apoptotic pathway gene signature (Molecular Signatures Database 
[MSigDB] M10169) (71), a rank-ordered gene list was made with 
fragments per kilobase per million mapped reads (FPKM) values 
from GDF6-overexpressing A375 melanoma cells as compared with 
empty vector control cells or from A375 cells expressing an shRNA 
targeting EGFP as compared with GDF6.1 shRNA-expressing cells. 
Default parameters of GSEA were used, and the Student’s t test was 
used to calculate significance. For GSEA based on TCGA samples, a 
rank-ordered gene list was derived from the expression profiles of 
385 melanoma samples, using the GDF6 expression level as a contin-
uous variable. Default parameters of GSEA were used, and Pearson’s 
correlation was used to calculate significance. Pathway analysis was 
performed using the WEB-based Gene SeT AnaLysis Toolkit (Web-
Gestalt) (72). Default parameters were used, except the minimum 
number of genes for a category was set at 10.
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